Effect of tirofiban on cardiac function, cardiomyocytes and inflammatory reaction in patients with acute myocardial infarction during emergency percutaneous coronary intervention
Purpose: To investigate the effect of tirofiban on cardiac function, cardiomyocytes and inflammatory reaction in acute myocardial infarction (AMI) patients during emergency percutaneous coronary intervention (PCI).
Methods: Ninety AMI patients who underwent PCI for two years in Hanchuan Hospital, Hanchuan People's Hospital/Wuhan University People's Hospital, Hanchuan, China, were involved in this retrospective studies. Two groups were used (46 patients per group). The study group was treated with tirofiban, while the control group was without tirofiban exposure. Changes in brain natriuretic peptide (BNP), left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) were determined using a biochemical analyzer, while the inflammatory cytokines i.e. interleukin -6 (IL-6), tumor necrosis factor (TNF-) and high sensitive C reactive protein (hs-CRP) were assayed with ELISA kits.
Results: One week after operation, a significantly lower level of BNP and a significantly higher level of LVEF were seen in the study group than in controls (p < 0.05). After the operation, the study group had significantly lower levels of CK, CK-MB and cTnI than the control group (p < 0.01). Pre-operative IL-6, TNF-α and hs-CRP levels were comparable between both groups (p > 0.05), but their post-operative values were significantly lower in the study group than in the control group (p < 0.01).
Conclusion: The use of tirofiban for AMI patients undergoing PCI significantly reduces BNP, increases LVEF, improves cardiac function, protects myocardial cells, reduces the level of inflammatory cytokines, and inhibits inflammatory reactions.
Keywords: Percutaneous coronary intervention, Acute myocardial infarction, Tirofiban, Cardiac function
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.